Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2023 June;71(3) > Minerva Cardiology and Angiology 2023 June;71(3):257-65



Publishing options
To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Cardiology and Angiology 2023 June;71(3):257-65

DOI: 10.23736/S2724-5683.22.06001-X


language: English

Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor

Monica VERDOIA 1, 2, Matteo NARDIN 2, 3, Rocco GIOSCIA 1, Harry SURYAPRANATA 4, Elvin KEDHI 5, Andrea ROGNONI 1, Giuseppe DE LUCA 6 on behalf of the Novara Atherosclerosis Study Group (NAS)

1 Division of Cardiology, Ospedale degli Infermi, ASL Biella, Biella, Italy; 2 Department of Translational Medicine, Eastern Piedmont University, Novara, Italy; 3 Department of Medicine, Spedali Civili of Brescia, Brescia, Italy; 4 Department of Cardiology, UMC St Radboud, Nijmegen, the Netherlands; 5 Department of Cardiology, ISALA Hospital, Zwolle, the Netherlands; 6 Division of Clinical and Experimental Cardiology, University Hospital of Sassari, Sassari, Italy

BACKGROUND: No study has so far evaluated the impact of chronic kidney disease (CKD) on high-on treatment platelet reactivity (HRPR) with ticagrelor and their prognostic consequences, that were therefore the aim of the present study.
METHODS: Patients on dual antiplatelet therapy with ASA+ticagrelor (90mg/twice a day) after percutaneous coronary revascularization for ACS were scheduled for platelet function assessment 30-90 days post-discharge. The primary study endpoint was defined as the occurrence of major cardiovascular events (a composite of cardiovascular death, recurrent acute coronary syndrome (MI), target vessel revascularization) at the longest available follow-up.
RESULTS: We included 396 patients, that were divided according to CKD (eGFR vs. 11.8%, P=0.84). At a mean follow-up of 939±581.4 days, 21.2% of the patients experienced the primary composite endpoint, with a similar rate of events in patients CKD or normal renal function (22.2% vs. 21.2% HR [95%CI]= 0.92[0.52-1.61], P=0.77), and no difference in survival, ischemic and bleeding endpoints. After correction for baseline differences CKD did not emerge as an independent predictor of either HRPR (adjusted OR [95%CI]=0.47 [0.18;1.25], P=0.13) or MACE (adjusted HR [95%CI]=0.66 [0.34-1.29] P=0.18).
CONCLUSIONS: In the present study we demonstrated that among ACS patients on DAPT with ASA and ticagrelor after PCI, renal failure is not associated with a higher rate of HRPR or to an increased risk of mortality or major ischemic and bleeding events.

KEY WORDS: Acute coronary syndrome; Platelet aggregation inhibitors; Percutaneous coronary intervention; Platelet aggregation; Patient outcome assessment

top of page